化合物 MMAE-d8|T10948|TargetMol

MMAE-d8
2070009-72-0

￥10890 1mg 起订

询价 5mg 起订

上海更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP4年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 一甲基澳瑞他汀E-d8

英文名称：: MMAE-d8

CAS号：: 2070009-72-0

品牌：: TargetMol

产地：: 美国

保存条件：: The compound is unstable in solution. Please use soon | Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature.

产品类别：: 抑制剂

货号：: T10948

Product Introduction

Bioactivity

名称	MMAE-d8
描述	MMAE-d8 is a deuterated compound of MMAE (Monomethyl Auristatin), suitable for isotope tracing. MMAE is a tubulin microtubule inhibitor that suppresses cancer cell mitosis and is frequently employed in antibody-drug conjugate (ADC) development.
体外活性	Antibody-drug conjugates (ADC) contain targeted antibodies with effective small molecule payloads. The ADC is produced against different receptors on the anaplastic large cell lymphoma L-82 line, but delivers the same cytotoxic payload (monomethyl auristatin E, MMAE). ADC-mediated cytotoxicity is not related to target expression or drug: antibody ratio. LC-MS was used to measure the concentration of MMAE in the L-82 tumor parallel cohort by the same treatment protocol. Although there was no difference in tumor volume between the treatment groups 3 days after administration, intratumoral MMAE measurements showed two patterns. First, the MMAE concentration in the tumor increases in proportion to the ADC dose, which corresponds to stronger antitumor activity. Second, intra-tumor MMAE concentrations obtained after treatment with cOKT9-vcMMAE and cAC10-vcMMAE were similar at each dose, which is consistent with the observation that tumors responded similarly to these two ADCs.
体内活性	In tumor xenograft models, the MMAE concentration in the tumor is always correlated with the degree of tumor growth inhibition. IHC analysis showed that tumors that were not combined with control treatment consisted of CD30 + and CD30 cells, presumably because they did not kill CD30 + or CD30- Karpas 299 cells. Only CD30-cells were found in tumors treated with cAC10-vcMMAF, indicating that cAC10-vcMMAF eliminated most CD30 + cells. Interestingly, at the end of the study, two tumors recurring from the treatment of cAC10-vcMMAE were also found to be CD30-, indicating that in the remaining two tumors, a small portion of CD30-cells may have escaped bystanders Kill.
存储条件	The compound is unstable in solution. Please use soon \| Powder: -20°C for 3 years \| Shipping with blue ice/Shipping at ambient temperature.
溶解度	10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (4.55 mM), Sonication is recommeded. DMSO : 80 mg/mL (110.19 mM), Sonication is recommended.
关键字	MMAE-d-8 \| MMAE-d8 \| MMAEd8 \| MMAE d8 \| D8-Monomethyl auristatin E \| ADCCytotoxin \| ADC Cytotoxin
相关产品	4-Isopropoxybenzoic acid \| Exatecan Mesylate \| Methotrexate disodium \| SN-38 \| Flubendazole \| Dexamethasone acetate \| Dexamethasone \| N-Phenylbenzylamine \| Paclitaxel \| 4'-Demethylepipodophyllotoxin \| Methotrexate \| Albendazole

一甲基澳瑞他汀E-d8|||Monomethyl auristatin E-d8|||Deuterated labeled MMAE|||D8-MMAE|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(13年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务